Joint Symposium: HTLV-1
Tracks
1
| Tuesday, November 7, 2017 |
| 11:30 AM - 1:00 PM |
| Royal Theatre |
Details
HTLV-1, is a sexually transmitted and blood-borne virus that is related to HIV (formerly called HTLV-3). Endemic foci are present throughout the world; however, prevalence is highest among Aboriginal Australians in central Australia where >50% of adults are infected in some communities. Infection is associated with a rapidly fatal leukaemia, inflammation in various organ systems including the lungs and central nervous system and an impaired immune response to other infections. In central Australia, an inability to control the number of infected peripheral blood lymphocytes increases risk of death, largely due to HTLV-1 associated pulmonary disease. Although HTLV-1 was identified as a priority in the National HIV Strategy, there has been no dedicated funding to characterise the natural history of HTLV-1 infection, or to develop a vaccine, public health response or therapeutic interventions. This symposium will be held to look in greater detail at the issues around HTLV-1. Note: Graham Taylor presents a plenary on this topic on Wednesday 8 November at 10.30am.
Speaker
Dr Lloyd Einsiedel
Executive Director Central Australia
Baker Heart And Diabetes Institute
Mr Shane Schinke
Project Officer
Baker IDI
Positive aspects of securing a diagnosis and effective treatment
11:45 AM - 11:55 AMBiography
Professor Damian Purcell
Professor of Virology and Theme Leader for Viral Infectious Diseases
Uni Melbourne, Doherty Institute
Novel viral genetics of Australian HTLV-1c
11:55 AM - 12:05 PMBiography
Dr. Damian Purcell is a Professor in Virology and head of the molecular virology laboratory in the Department of Microbiology and Immunology at the University of Melbourne. He is Viral Infectious Diseases theme leader and GVN co-director at the Peter Doherty Institute, and on the executive committee of AVS, and ACH2. His research is in HIV and HTLV: gene expression, preventive vaccines, and antiviral and curative therapeutics.
Dr. Genoveffa Franchini
Senior Investigator
NIH National Cancer Institute
Viral factors that contribute to HTLV-1 persistence
12:05 PM - 12:15 PMBiography
Dr. Genoveffa Franchini is a hematologist and retrovirologist who has pioneered research on oncogenes and human retroviruses (HTLVs and HIVs). Her work has furthered the understanding of HTLV-1 pathogenesis and gene regulations, and has led to the first partially efficacious HIV vaccine in humans.
Professor Graham Taylor
Professor
Imperial College London
Clinical Interventions for HTLV-1 Associated Diseases
12:30 PM - 12:50 PMBiography
Qualified MB ChB Birmingham 1981. Trained in Internal Medicine in the West Midlands and South Wales. Appointed Chief Medical Officer (Medicine) Solomon Islands 1988 where first interested in HTLVs. Joined Imperial College and initiated HTLV-1 clinic 1992. Runs the National HTLV clinical service, diagnostic lab and retroviruses translational research group.
Dr Fabiola Martin
Senior Clinical Lecturer
University Of York & University of Queensland
The National Centre For Human Retrovirology: HTLV Hub And Spoke Care Provision In The UK
12:15 PM - 12:30 PMBiography
Fabiola Martin is an expert in Sexual Health, HIV and HTLV Medicine. Her MDRes was in HTLV-1 associated myelopathy (2009). She is a member of the executive board of the International Retrovirology Association. She is the current Head of the MD Program Admissions at the Medical Faculty/ University of Queensland.
Q&A
Q&A
12:50 PM - 1:00 PMBiography
